Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 193


CHM-1 induces apoptosis via p38-mediated upregulation of DR5 expression in human ovarian cancer SKOV3 cells.

Lee JC, Chou LC, Huang CH, Chung JG, Huang LJ, Lee KH, Hung MC, Way TD, Kuo SC.

Eur J Pharmacol. 2011 Nov 16;670(1):96-104. doi: 10.1016/j.ejphar.2011.08.006. Epub 2011 Sep 3.


CHM-1, a new vascular targeting agent, induces apoptosis of human umbilical vein endothelial cells via p53-mediated death receptor 5 up-regulation.

Tsai AC, Pan SL, Sun HL, Wang CY, Peng CY, Wang SW, Chang YL, Kuo SC, Lee KH, Teng CM.

J Biol Chem. 2010 Feb 19;285(8):5497-506. doi: 10.1074/jbc.M109.036277. Epub 2009 Dec 11.


The synthesized 2-(2-fluorophenyl)-6,7-methylenedioxyquinolin-4-one (CHM-1) promoted G2/M arrest through inhibition of CDK1 and induced apoptosis through the mitochondrial-dependent pathway in CT-26 murine colorectal adenocarcinoma cells.

Chou LC, Yang JS, Huang LJ, Wu HC, Lu CC, Chiang JH, Chen KT, Kuo SC, Chung JG.

J Gastroenterol. 2009;44(10):1055-63. doi: 10.1007/s00535-009-0111-1. Epub 2009 Aug 14.


CHM-1, a novel synthetic quinolone with potent and selective antimitotic antitumor activity against human hepatocellular carcinoma in vitro and in vivo.

Wang SW, Pan SL, Huang YC, Guh JH, Chiang PC, Huang DY, Kuo SC, Lee KH, Teng CM.

Mol Cancer Ther. 2008 Feb;7(2):350-60. doi: 10.1158/1535-7163.MCT-07-2000.


Trichostatin A sensitizes human ovarian cancer cells to TRAIL-induced apoptosis by down-regulation of c-FLIPL via inhibition of EGFR pathway.

Park SJ, Kim MJ, Kim HB, Sohn HY, Bae JH, Kang CD, Kim SH.

Biochem Pharmacol. 2009 Apr 15;77(8):1328-36. doi: 10.1016/j.bcp.2008.12.027. Epub 2009 Jan 24.


Activation of p38 MAPK by damnacanthal mediates apoptosis in SKHep 1 cells through the DR5/TRAIL and TNFR1/TNF-α and p53 pathways.

Lin FL, Hsu JL, Chou CH, Wu WJ, Chang CI, Liu HJ.

Eur J Pharmacol. 2011 Jan 10;650(1):120-9. doi: 10.1016/j.ejphar.2010.10.005. Epub 2010 Oct 14.


Tocotrienols induce apoptosis in breast cancer cell lines via an endoplasmic reticulum stress-dependent increase in extrinsic death receptor signaling.

Park SK, Sanders BG, Kline K.

Breast Cancer Res Treat. 2010 Nov;124(2):361-75. doi: 10.1007/s10549-010-0786-2. Epub 2010 Feb 16.


Seleno-cyclodextrin sensitises human breast cancer cells to TRAIL-induced apoptosis through DR5 induction and NF-κB suppression.

Lin T, Ding Z, Li N, Xu J, Luo G, Liu J, Shen J.

Eur J Cancer. 2011 Aug;47(12):1890-907. doi: 10.1016/j.ejca.2011.04.004. Epub 2011 May 10.


Curcumin-induced apoptosis in ovarian carcinoma cells is p53-independent and involves p38 mitogen-activated protein kinase activation and downregulation of Bcl-2 and survivin expression and Akt signaling.

Watson JL, Greenshields A, Hill R, Hilchie A, Lee PW, Giacomantonio CA, Hoskin DW.

Mol Carcinog. 2010 Jan;49(1):13-24. doi: 10.1002/mc.20571.


Up-regulation of death receptor 4 and 5 by celastrol enhances the anti-cancer activity of TRAIL/Apo-2L.

Zhu H, Liu XW, Ding WJ, Xu DQ, Zhao YC, Lu W, He QJ, Yang B.

Cancer Lett. 2010 Nov 28;297(2):155-64. doi: 10.1016/j.canlet.2010.04.030. Epub 2010 Jun 1.


CAAT/enhancer binding protein homologous protein-dependent death receptor 5 induction is a major component of SHetA2-induced apoptosis in lung cancer cells.

Lin YD, Chen S, Yue P, Zou W, Benbrook DM, Liu S, Le TC, Berlin KD, Khuri FR, Sun SY.

Cancer Res. 2008 Jul 1;68(13):5335-44. doi: 10.1158/0008-5472.CAN-07-6209.


Butein sensitizes human hepatoma cells to TRAIL-induced apoptosis via extracellular signal-regulated kinase/Sp1-dependent DR5 upregulation and NF-kappaB inactivation.

Moon DO, Kim MO, Choi YH, Kim GY.

Mol Cancer Ther. 2010 Jun;9(6):1583-95. doi: 10.1158/1535-7163.MCT-09-0942. Epub 2010 Jun 1.


Death receptor regulation and celecoxib-induced apoptosis in human lung cancer cells.

Liu X, Yue P, Zhou Z, Khuri FR, Sun SY.

J Natl Cancer Inst. 2004 Dec 1;96(23):1769-80.


Novel quinolone CHM-1 induces apoptosis and inhibits metastasis in a human osterogenic sarcoma cell line.

Hsu SC, Yang JS, Kuo CL, Lo C, Lin JP, Hsia TC, Lin JJ, Lai KC, Kuo HM, Huang LJ, Kuo SC, Wood WG, Chung JG.

J Orthop Res. 2009 Dec;27(12):1637-44. doi: 10.1002/jor.20937.


Structural and functional analysis of the interaction between the agonistic monoclonal antibody Apomab and the proapoptotic receptor DR5.

Adams C, Totpal K, Lawrence D, Marsters S, Pitti R, Yee S, Ross S, Deforge L, Koeppen H, Sagolla M, Compaan D, Lowman H, Hymowitz S, Ashkenazi A.

Cell Death Differ. 2008 Apr;15(4):751-61. doi: 10.1038/sj.cdd.4402306. Epub 2008 Jan 25.


A novel p53 rescue compound induces p53-dependent growth arrest and sensitises glioma cells to Apo2L/TRAIL-induced apoptosis.

Weinmann L, Wischhusen J, Demma MJ, Naumann U, Roth P, Dasmahapatra B, Weller M.

Cell Death Differ. 2008 Apr;15(4):718-29. doi: 10.1038/sj.cdd.4402301. Epub 2008 Jan 18.


Anti-gout agent allopurinol exerts cytotoxicity to human hormone-refractory prostate cancer cells in combination with tumor necrosis factor-related apoptosis-inducing ligand.

Yasuda T, Yoshida T, Goda AE, Horinaka M, Yano K, Shiraishi T, Wakada M, Mizutani Y, Miki T, Sakai T.

Mol Cancer Res. 2008 Dec;6(12):1852-60. doi: 10.1158/1541-7786.MCR-08-0012.


YM155 sensitizes triple-negative breast cancer to membrane-bound TRAIL through p38 MAPK- and CHOP-mediated DR5 upregulation.

Pennati M, Sbarra S, De Cesare M, Lopergolo A, Locatelli SL, Campi E, Daidone MG, Carlo-Stella C, Gianni AM, Zaffaroni N.

Int J Cancer. 2015 Jan 15;136(2):299-309. doi: 10.1002/ijc.28993. Epub 2014 Jun 5.

Items per page

Supplemental Content

Write to the Help Desk